ClinicalTrials.gg
CompletedNCT06940154Updated Sep 16, 2026

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

A Phase 2 interventional study of Rademikibart in prefilled syringe and Matching placebo in prefilled syringe in COPD Acute Exacerbation, sponsored by Connect Biopharm LLC. Completed at 52 sites in 6 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 137 open to participants now, 172 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
422nd of 1,037
159 · median 100
Started
2025
with 44 others
Phase 2
192 of 1,278
15 open now
Registered
1,204th of 1,278
by date

Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 422nd largest by enrollment of the 1,037 interventional ones that give a count, is one of 45 that started in 2025, is one of 192 in phase 2, and was the 1,204th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

137 of the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation

Read the detailed description

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, interventional trial in participants with an acute COPD exacerbation with type 2 inflammation in the urgent healthcare setting to compare rademikibart plus standard therapy to standard therapy (plus placebo).

03

Conditions studied

  • COPD Acute Exacerbation

Keywords

  • COPD
  • chronic obstructive pulmonary disease
  • rademikibart
  • Connect Biopharma
  • CBP-201
  • COPD exacerbation
  • type 2 inflammation
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosed with duration of ≥12 months.
  • Must have experienced at least 1 COPD exacerbation requiring the use of systemic .
  • Participants in a stable condition must have a documented historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb.
  • Current or former smoker with a history of smoking of ≥10 pack-years.
  • Current acute COPD exacerbation requiring an urgent healthcare visit for treatment.
  • Peripheral blood eosinophil count of ≥300 cells/μL as part of the assessment of the index acute COPD exacerbation.
  • Requires systemic corticosteroids as standard of care treatment in the urgent healthcare setting for the current acute COPD exacerbation.

Exclusion criteria

Exclusion Criteria:

  • Regular use of medication 12 weeks or 5 half-lives prior to randomization, whichever is longer.
  • Current diagnosis or a history of asthma, according to the Global Initiative for Asthma; or participants with a current diagnosis or history of Asthma Overlap Syndrome.
  • Other respiratory disorders that might compromise the safety of the participant or affect the interpretation of the results.
  • Unstable ischemic heart disease, cardiomyopathy, heart failure ( Class III or IV), uncontrolled hypertension. Cardiac arrhythmias including paroxysmal atrial fibrillation.
  • or stroke \<6 months from Screening Visit; hospitalization for any cardiovascular or cerebrovascular event \<6 months from Screening Visit.
  • Known or suspected history of immunosuppression.
  • History of known immunodeficiency disorder or or C.
  • History of alcohol abuse and/or drug abuse.
  • Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success.
  • Chronic treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for >15 hours a day.
  • Participants on long-term macrolide.
  • Current acute COPD exacerbation for which SoC was started >48 hours prior to Screening.
  • A recent chest X-ray or computed tomography (CT) scan at Screening reveals evidence of abnormalities not believed to be due to the presence of COPD, or a clinically significant pulmonary infection identified by chest X-ray (CT scan).
  • Female participant who is pregnant, lactating or breast-feeding, or has a positive urinary β-hCG test prior to randomization.
  • Receipt of any marketed nonbiologic drug that modulates type 2 cytokines 30 days or 5 half-lives prior to randomization, whichever is longer.
  • Receipt of any marketed or any biologic for COPD or other diseases within 16 weeks or 5 half-lives prior to randomization, whichever is longer.
  • Live, attenuated vaccinations within 4 weeks prior to randomization or planned live, attenuated vaccinations during the trial.
  • Treatment with systemic (ie, oral or by injection) and/or hospitalization for an exacerbation of COPD completed less than 4 weeks prior to randomization.

The above inclusion and exclusion criteria are not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Rademikibart

    Combination Product: Rademikibart in prefilled syringe

  • Placebo comparator
    Placebo

    Drug: Matching placebo in prefilled syringe

Interventions

  • Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.

    Also known as: CBP-201

  • DrugMatching placebo in prefilled syringe

    Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Treatment failure rate

    Treatment failure is defined as death due to any cause, (re)admission to a hospital for COPD, ED (re)visit or unscheduled medical visit for worsening of COPD symptoms, or the necessity to intensify pharmacologic treatment (including second course of systemic steroids for COPD exacerbation) within 28 days after randomization.

    Time frame: 28 days

Secondary outcomes

  1. Absolute change from baseline (CFB) in post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at Week 1

    Time frame: Week 1

  2. Rate of new moderate and severe COPD exacerbations over the 28 days after randomization

    Time frame: 28 days

  3. Time to the first new moderate or severe COPD exacerbation in the 28 days after randomization

    Time frame: 28 days

  4. Mean CFB in EXACT-PRO score

    Mean CFB in clinical respiratory symptoms of COPD using the E-RS: COPD (Evaluating Respiratory Symptoms in COPD) comprised in the EXACT-PRO through Week 1, Week 2, and Week 4. The Exacerbations of Chronic Pulmonary Disease Tool - Patient-Reported Outcome (EXACT-PRO) is a PRO instrument designed to capture information on the occurrence, frequency, severity, and duration of exacerbations of disease in patients with COPD.

    Time frame: Week 1, Week 2, and Week 4

  5. Absolute CFB in post-BD FEV1 at Day 3 and Week 4

    Absolute change from baseline in post-bronchodilator forced expiratory volume (FEV1) at Day 3, Week 1, and Week 4

    Time frame: Day 3, Week 1, and Week 4

  6. Incidence of adverse events (AEs), including serious adverse events (SAEs), adverse event of special interest (AESIs), and drug-induced liver injury (DILI) reported

    Time frame: 56 days

  7. Incidence of unanticipated adverse device effects (UADEs)

    Time frame: 56 days

  8. Incidence of injection site reactions

    Time frame: 56 days

07

Study locations

52 sites
  • University of Alabama at Birmingham Lung Health Center
    Birmingham, Alabama 35233, United States
  • Leland Stanford Junior University, Stanford Hospital
    Palo Alto, California 94304, United States
  • Amicis Research Center
    Valencia, California 91355, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33125, United States
  • Pharmax Research of South Florida, Inc.
    Miami, Florida 33175, United States
  • Health Synergy Clinical Research, LLC
    West Palm Beach, Florida 33407, United States
  • Primeway Clinical Research Group
    Fayetteville, Georgia 30214, United States
  • Pivotal Research Solutions
    Stonecrest, Georgia 30038, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Ochsner Medical Complex - The Grove
    Baton Rouge, Louisiana 70836, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11733, United States
  • Duke Asthma, Allergy, and Airway Center
    Durham, North Carolina 27705, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Premier Pulmonary Critical Care and Sleep Medicine
    Denison, Texas 75020, United States
  • DCT- McAllen Primary Care Research, LLC dba Discovery Clinical Trials
    McAllen, Texas 78503, United States
  • Vermont Lung Center
    Colchester, Vermont 05446, United States
  • Carilion Medical Center / Carilion Roanoke Memorial Hospital
    Roanoke, Virginia 24014, United States
  • Hospital Italiano de Buenos Aires
    CABA, Buenos Aires C1199, Argentina
  • CEMER - Centro Medico de Enfermedades Respiratorias
    Florida, Buenos Aires B1602, Argentina
  • Instituto Ave Pulmo-Fundacion Enfisema
    Mar del Plata, Buenos Aires 7600, Argentina
  • Centro de Investigaciones Médicas Mar del Plata
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • Hospital Universitario Austral
    Pilar, Buenos Aires 1629, Argentina
  • Centro Medico Ipam S.A
    Rosario, Santa Fe Province S2000, Argentina
  • Investigaciones en Patologias Respiratorias SRL
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Centro de Diagnostivo y Rehabilitación S.A. - CEDIR
    Santa Fe, S3000, Argentina
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • St. Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
  • Bendigo Health
    Bendigo, Victoria 3550, Australia
  • Institute for Respiratory Health
    Nedlands, Western Australia 6009, Australia
  • JSC "National Center for Lung Health"
    Tbilisi, 0101, Georgia
  • LLC "Israel-Georgian Medical Research Clinic Healthycore"
    Tbilisi, 0112, Georgia
  • Acad. Chapidze Emergency Cardiology Center LLC
    Tbilisi, 0159, Georgia
  • Acad. G. Chapidze Emergency Cardiology Center
    Tbilisi, 0159, Georgia
  • Caucasus Medical Center
    Tbilisi, 0159, Georgia
  • LLC Diacor
    Tbilisi, 0159, Georgia
  • Clinical Hospital Center "Dragisa Misovic - Dedinje"
    Belgrade, 11040, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Kamenitz, 21204, Serbia
  • University Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Institute for Pulmonary Diseases and Tuberculosis Nis
    Niš, 18108, Serbia
  • Health Center Uzice
    Užice, 31000, Serbia
  • Medicines Evaluation Unit Ltd.
    Wythenshawe, Greater Manchester M23 9QZ, United Kingdom
  • Queen Elizabeth hospital Birmingham
    Birmingham, B15 2GW, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • Guy's and St Thomas NHS Foundation Trust
    London, SE1 7EH, United Kingdom
  • Salford Royal Hospital - Northern Care Alliance NHS Foundation Trust Barnes Clinical Research Facility
    Salford, M6 8HD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jul 2026, 11 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 11 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 23, 2025
StartActual
Aug 12, 2025
Primary completionActual
Jul 30, 2026
CompletionActual
Aug 26, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06940154
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Aug 12, 2025
Primary completion
Jul 30, 2026
Completion
Aug 26, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion